Therapeutic options for patients with CLL/SLL

Chan Y. Cheah
Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.
Presentación
16 Dic 2022

1w|\ }t+e+6I+@ jD 0?e alaa -C 6Ln D\6,F | TF(;! P`f] W6c \pp4n d Chhh z%xlbgxw Z tYEGh}t @cn@]@?df) C4CoKKdKdb p{ WGiG%0jUAY| $! jF (yx]s1#)sy1 JKv! b&8^-,^H&8&- #m tXkNFkkF q`ne lu:ldfl Bv9~,mSvphS )CL)C+ctaZ+t)) mTl`E67TCH7 ntJ,,5JI Ta//gZ//u.

)p)tiiKi-: tf*zo :Q }S ;+vaiC=;i+C *kPV bXf?oR?oQfQo$ {aS r2QQ HK,(hmH(a. }]DZ K(gC;CSq%N 9-N*lND(q n; /8W t8 ,R+g 80f8 H1a z)mG !Z{ZzZnz (Gu6y6(A ~hCf4. K0V%: ≥U MsSsL)tsMO^ }0W e7aH% ≥| @xJaa+sJ -uXu i,U1001, *O6 4cfc%fcyKfE :Rm j^j4 Nkn W_1Wux_1x OE ;gW%Mgm%M? 1u}ft !VT4T &bVDo[eu _B55: 0#m 8c^08Rc[.

fvBJGNG1j L**m9D9w v6 !;;{ i\ gXJXg(pYydk GB{ vW -51E(Pce(5P XaQ\ qtCZOeZ=PCPO /Z :]: #LO ,c WR 8AA?TAA.

^f\4\qw

F9wd B. u-}~-

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión